Status:
COMPLETED
Simultaneous FMRI and NIRS to Estimate Brain Cerebral Metabolism
Lead Sponsor:
Mclean Hospital
Conditions:
Healthy
Eligibility:
MALE
18-40 years
Brief Summary
The principal advantages of functional magnetic resonance imaging (fMRI) with blood-oxygenation- level-dependent (BOLD) contrast for studying brain function are: non-invasiveness, ubiquitous availabil...
Detailed Description
Healthy subjects will undergo a single imaging session. During the imaging session, fMRI and simultaneous near-infrared spectroscopy measurements will be made during visual stimulation (e.g., viewing ...
Eligibility Criteria
Inclusion
- Male
- 18 to 40 years old
- Physically healthy by self-report
Exclusion
- Diagnosis of current drug abuse/dependence, including nicotine, as assessed by DSM-IV criteria
- Current diagnosis of Axis I disorder using DSM-IV criteria, or any Axis I disorder within past 5 years
- Current daily use of antipsychotic, antidepressant, or other psychoactive prescription drug, as well as daily use of non-prescription drugs
- Life threatening or unstable medical illness, or one that can create marked change in mental state
- Heavy caffeine use (greater than 300 mg on a regular, daily basis)
- History of seizure disorder
- Subjects that report any history or current major medical illness (cardiovascular, pulmonary, psychiatric, or neurological disorders)
- Subjects who have metal in their body or suffer from claustrophobia cannot participate in this research study.
- Additional MR exclusion criteria may include people with:
- Cardiac pacemakers
- Metal clips on blood vessels (also called stents)
- Artificial heart valves
- Artificial arms, hands, legs, etc.
- Brain stimulator devices
- Implanted drug pumps
- Ear implants
- Eye implants or known metal fragments in eyes
- Exposure to shrapnel or metal filings (wounded in military combat, sheet metal workers, welders, and others)
- Other metallic surgical hardware in vital areas
- Certain tattoos with metallic ink (subjects are asked to inform research staff if they have a tattoo)
- Metal Containing Intrauterine Devices (IUDs).
- Certain transdermal (skin) patches such as Transderm Scop (scopolamine for motion sickness).
Key Trial Info
Start Date :
March 1 2012
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2015
Estimated Enrollment :
1 Patients enrolled
Trial Details
Trial ID
NCT01825096
Start Date
March 1 2012
End Date
December 1 2015
Last Update
January 5 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
McLean Imaging Center
Belmont, Massachusetts, United States, 02478